Get the Stockscreener App
0.56
1.75%
-0.010
Galmed Pharmaceuticals Ltd stock is traded at $0.56, with a volume of 25,421.
It is down -1.75% in the last 24 hours and up +6.67% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
See More
Previous Close:
$0.57
Open:
$0.559
24h Volume:
25,421
Relative Volume:
0.01
Market Cap:
$4.30M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-0.2403
EPS:
-2.3308
Net Cash Flow:
$-6.32M
1W Performance:
-1.82%
1M Performance:
+6.67%
6M Performance:
-32.77%
1Y Performance:
-72.41%
1-Day Range:
$0.542
$0.57
1-Week Range:
$0.5403
$0.5749
52-Week Range:
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.56 | 4.30M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - AOL.com
Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54Trading Ideas - dars.gov.et
Galmed Pharmaceuticals (GLMD) Slides 12% as Selling Pressure Intensifies Near Key SupportMarket Neutral Pair - dars.gov.et
GLMD Forecast — Price Target — Prediction for 2027 - TradingView
GLMD Should I Buy - Intellectia AI
Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD) - TradingView
GPH Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to book forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to sales forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure - The Globe and Mail
Galmed completes acquisition of medical device firm Colospan - Investing.com UK
Galmed Pharmaceuticals finishes restructured Colospan deal - grafa.com
Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd. - TradingView
Galmed completes acquisition of medical device firm Colospan By Investing.com - Investing.com Nigeria
Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout - Stock Titan
Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout - Stock Titan
Galmed buys CG-100 maker Colospan, eyes faster EU sales - Stock Titan
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Declines 3.37% as Shares Approach Key Support at $0.55Put Flow Alert - dars.gov.et
Galmed Pharmaceuticals Ltd (GLMD) Institutional Confidence - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galmed Pharmaceuticals (GLMD) Slips 7.31% as Stock Tests Key Support at $0.54New Highs New Lows - newsline.com
GLMD Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseEarnings Recovery Stocks - newsline.com
Maxim Group Maintains Galmed Pharmaceuticals(GLMD.US) With Hold Rating, Announces Target Price $0.55 - Moomoo
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market - Fierce Biotech
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
Galmed to acquire medical device firm Colospan for $4.5M By Investing.com - Investing.com Australia
Galmed to Acquire Colospan in Deal Expanding GI Medtech Platform - citybiz
Galmed Pharmaceuticals to Acquire Colospan, targeting $6B GI market - grafa.com
Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion - geneonline.com
Galmed to acquire medical device firm Colospan for $4.5M - Investing.com UK
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent - Stock Titan
Galmed (NASDAQ: GLMD) registers 7.5M shares; agrees to buy Colospan - Stock Titan
[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer) | GLMD SEC FilingForm 6-K - Stock Titan
Press Release: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Moomoo
GLMD News | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo - TipRanks
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):